Half-year report · Q2
4886.TEDINET S100UNSK
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥32.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥62.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥31.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥3.1bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥6.5bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.1bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥5.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥7.5bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥4.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥88.3bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥90.7bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥91.9bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥24.1bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥28.8bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥64.2bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥61.9bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥58.6bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥12.7bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥13.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥13.7bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥19.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.5bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥90.36 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥266.51 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥145.93 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 72.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.8% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥151m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥113m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥38m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥4m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥38m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥38m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥652m |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥177m |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥28.6bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥28.6bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥32.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥32.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥38m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥4.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥108m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥80m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥27m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | −¥61m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥27m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥27m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥585m |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥44m |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥28.4bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥28.4bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥3.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥31.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥31.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥27m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥3.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 456
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)清陽監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)中市 俊也 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)槇田 憲一郎 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 31648000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 32371000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 62843000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 3096000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 3312000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 6522000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 4129000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 2560000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 7545000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 4251000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 2745000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 8127000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 58621000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 64192000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 61930000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 91920000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 88263000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 90745000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 145.93 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 90.36 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 266.51 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.638 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.727 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.682 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | 3097000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 1159000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 1486000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | 1382000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -1783000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | 1706000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | -2539000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | -2406000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -3943000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 19446000000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 13705000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 16738000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 30563199 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 30563199 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 30563199 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 30563199 | |
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 2963000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.1044 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |